Matching of XEN®45 and PRESERFLO™ MicroShunt cases: Outcomes of a 3-year follow-up.

PLoS One · 2025 · PMC12578230 · PMID 41171739

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

A notable difference was observed in the rate of surgical revisions, with PRESERFLO showing a lower revision rate (28.6%) compared to XEN (42.9%), although this difference did not reach statistical significance.

also in 111,027 other papers

showed a trendno p-value reported

Regarding surgical success, using stricter criteria (Category A: IOP ≤ 15 mmHg without medication), PRESERFLO showed a trend toward higher success rates at one year (45.9% vs. 34.2% for XEN), though not statistically significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.